Windjammer Capital Acquires Bio X Cell

Windjammer Capital Investors (“Windjammer”), a national private equity investment firm focused on control equity investments in middle-market businesses, has announced the acquisition of Bio X Cell, LLC (“BXC” or the “Company”) in partnership with management. Bio X Cell is a leading producer of monoclonal antibodies (mAbs) for use in both in vivo and in vitro pre-clinical research applications. Founded by Dr. Klaus Lubbe in 1997 as a contract manufacturer of antibodies, BXC has evolved to become the only pure-play in vivo mAbs manufacturer of scale, providing “off-the-shelf”, ultra-pure, low endotoxin antibodies.

Read the full article: Windjammer Capital Acquires Bio X Cell //


Leave a Comment

Your email address will not be published.

Scroll to Top